There were no differences between the groups in the use of other PD drugs, including dopamine agonists, COMT inhibitors, anticholinergic agents, and amantadine. Cumulative L-dopa exposure was ...
Alternatives to L-dopa for initial treatment of Parkinson's disease (PD) should be considered for patients younger than 65-70 years. Nonmotor symptoms are very common in PD and include ...
NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...
Anticonvulsants used to treat epilepsy work on GABA. And drugs used to treat Parkinson’s disease, such as L-DOPA, promote dopamine function. Other Brain Cells (Glia) Although neurons are ...